who discovered glp-1 Scientists the Glucagon Yusa peptide (GLP-1) were selected as winners of the Lasker P Metabolic Messengers: glucagon-like peptide 1

But this is only the beginning, with Ozempic and Wegovy both losing patent protection in China in 2026, in Europe and Japan in 2031, and in the US in 2032

In response, beverage companies are rethinking how they create value, focusing less on frequency and more on the quality of each drinking occasion

[7] [8] GLP-1 receptor agonists (such as semaglutide, liraglutide, and dulaglutide) are now widely prescribed medications for type 2 diabetes and obesity management, approved by the MHRA and recommended in NICE guidelines (NG28 for type 2 diabetes

Managing GI side effects and titration strategies Gastrointestinal adverse events affect 40-70% of treated patients [25], primarily consisting of: Nausea (15-50%) Diarrhea (5-25%) Vomiting (5-10%) Slow titration remains fundamental to mitigating these effects

Simultaneously, the state of calorie deficit itself creates a catabolic environment, where the body breaks down tissue to meet energy demands

Data availability All relevant data are available from the authors and/or included in the manuscript or Supplementary Information